Navigation Links
BD Announces Appointment of William A. Kozy as Chief Operating Officer
Date:11/6/2012

FRANKLIN LAKES, N.J., Nov. 6, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William A. Kozy as Chief Operating Officer, effective today. Mr. Kozy adds this title to his current title of Executive Vice President. He will continue to report to Vincent A. Forlenza, Chairman, Chief Executive Officer and President.

"Bill's new title reflects his leadership role and the additional responsibilities that he has taken on over the last year, including oversight of BD's three business segments and working with me to drive BD's growth and innovation focus," said Mr. Forlenza.

Mr. Kozy, 60, joined BD in 1974 in a sales role in the BD Division selling laboratory products. This focus on blood collection eventually led to his first general management position as President of BD Vacutainer® Systems. His subsequent leadership positions include, among others, President, BD Worldwide Injection Systems; Senior VP, Company Operations; President, BD Diagnostics; and Executive Vice President.

Mr. Kozy has a B.A. cum laude in English from Kenyon College in Ohio.

About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contacts:
Colleen T. White, Corporate Communications – 201-847-5369; colleen_white@bd.com
Monique N. Dolecki, Investor Relations – 201-847-5378; monique_dolecki@bd.com


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Micell Technologies Announces Issuance of Core Technology Patent
2. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
3. Rigel Announces Third Quarter 2012 Financial Results
4. Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
5. Mindray Medical Announces Top Management Change
6. Cepheid Announces Executive Vice President Emerging Markets
7. Cardica Announces Fiscal 2013 First Quarter Financial Results
8. PDL BioPharma Announces Third Quarter 2012 Financial Results
9. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
10. Global Green, Inc. Announces DTC Eligibility
11. Psychemedics Corporation Announces 3rd Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)...  Maxor National Pharmacy Services, LLC ("Maxor"), a leading ... Leah Bailey as General Counsel.  Bailey will serve ... With more than 13 years of experience ... on health care, Bailey joins the Maxor team coming ... advised the PBM, Specialty, and Mail Order business areas ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Youth Futures ... great success and feedback from high school and college students who have participated in ... held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... Louisiana (PRWEB) , ... March 29, 2017 , ... ... in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of ... Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the counter ...
Breaking Medicine News(10 mins):